Muse bio secures $23M Series B funding led by Venrock investor group

Tuesday February 28, 2017 0 comments Tags: Boulder, Muse bio, Venrock, Bryan Roberts, Dr. Kevin Ness, ForgeCraft

BOULDER -- Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced completion of a $23 million Series B financing.Muse_bio_logoUSE

The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.

"The simplification of single-cell, multiple edit genome engineering to an automated, benchtop process will democratize gene writing in the same way that Illumina's efforts did for gene reading 10 years ago,” said Bryan Roberts, Venrock partner. 

“It will enable many more scientists to rapidly conduct genomic research and develop new products across multiple applications in healthcare, agriculture, and industrial biotechnology. Muse bio can fulfill this promise."

"We are excited to be funded by this high-quality group of investors with a proven track record of success,” said Kevin Ness, Muse bio CEO.

“They recognize the value of Muse bio's technology, which enables scientists to make multiple, clearly defined genomic modifications at any site within a cell's genome in a high-throughput and cost-effective manner.

"The proceeds from this financing will allow us to accelerate our timelines to bring ForgeCraft™ to scientists worldwide."